CARs are synthetic immune receptors that connect a single-chain variable fragment (scFv), derived from a monoclonal antibody, to T cell signaling domains to eradicate tumor cells independent of the major histocompatibility complex (MHC). This evidence concerns the gene HLA-C and neoplasm.